John Lambert Appointed as Chairman of the Board of ImmunoBiology Ltd (“ImmBio” Cambridge, UK; 31 October 2012: The Directors of ImmunoBiology Ltd ((“ImmBio”) are pleased to announce the appointment of John Lambert as Chairman, with immediate effect. John has a wealth of experience in the vaccine industry including as President of Chiron Corporation ahead of its acquisition by Novartis. Prior to Chiron, John was President of Aventis Pasteur MSD, the joint vaccine business of Merck and Sanofi Pasteur in Europe. More recently John has held a number of non-executive positions, including at Acambis, subsequent acquired by Sanofi and Novavax. He was M&A advisor to Crucell John Lambert said: “I am pleased to be joining ImmBio at this exciting stage, with the additional funding being used to progress to human clinical trials to validate the positive findings from pre-clinical trials”. Graham Clarke. CEO, added “I am absolutely delighted that John has agreed to become Chairman of ImmBio. His wealth of experience will be enormously beneficial in taking ImmBio forward into its next stage of evolution”.